AI Generated Image
Some achieve dramatic hair regrowth from common arthritis drug: study
New York Post • • health
Key Points:
- A new study shows that upadacitinib (Rinvoq), an arthritis drug, can significantly promote hair growth in people with severe alopecia areata, an autoimmune condition causing patchy hair loss.
- The trial involved participants with at least 50% scalp hair loss, with 45% on a 15 mg dose and 55% on a 30 mg dose regrowing enough hair to cover at least 80% of their scalp after six months.
- Rinvoq outperformed existing treatments like baricitinib, rilecitinib, and deuruxolitinib, with many participants achieving up to 90% or total scalp hair regrowth, including eyebrows and eyelashes.
- Although not yet FDA-approved for alopecia areata in the US, Rinvoq was recently approved for this use in the European Union, and doctors may prescribe it off-label in the US.
- AbbVie, the drug’s maker, emphasizes the importance of this treatment option for patients facing the physical and mental challenges of severe alopecia areata.
